Chromoblastomycosis Treatment Market 2018 – 2023 Projected to Grow Radiantly by Top Players Revenue and Growth Rate
Market Scenario:
Chromoblastomycosis is a fungal infection caused by species
such as Fonsecaea pedrosoi, Cladophialophora carrionii, Phialophora verrucosa,
Fonsecaea compacta, Rhinocladiella aquaspersa, Chaetomium funicola and others.
This disease mostly affects the skin and the subcutaneous tissues. Globally,
there is about a million type of fungal species, yet nearly 300 are capable of
causing infections or disease in humans. Most of these cases are seen in people
with compromised immune systems and can occur almost in any part of the body.
A type of fungal infection known as systemic mycosis is
affecting the internal organs of the body. During this, fungal infection can
spread and affect other organs of the body. The rising cases of immunological
diseases is a reason for increased probability of systemic mycosis. Thus, the
developing novel treatment for chromoblastomycosis with fewer side effects is
the primary objective of manufacturing companies.
The newly launched azoles such as voriconazole and
itraconazole, are the gold standard drugs for antifungal therapy.
Get Exclusive Sample Report @ https://www.marketresearchfuture.com/sample_request/5685
Intended
Audience
·
Chromoblastomycosis treatment Drug Suppliers
·
Chromoblastomycosis treatment Drug Manufacturers
·
Research and Development (R&D) Companies
·
Medical Research Laboratories
·
Academic Medical Institutes and Universities
Segmentation:
The global chromoblastomycosis treatment market is segmented
on the basis of species, types, diagnosis, treatment, and end-users.
On the basis of the species, the global chromoblastomycosis
treatment market is segmented into Fonsecaea pedrosoi, Cladophialophora
carrionii, Phialophora verrucosa, Fonsecaea compacta, Rhinocladiella
aquaspersa, Chaetomium funicola, and others.
On the basis of the disease type, the global
chromoblastomycosis treatment market is segmented into nodular type, tumoral
type, verrucous type, plaque type, and others.
On the basis of the diagnosis, the global chromoblastomycosis
treatment market is segmented into blood test, immunodiagnosis, histopathology
and mycological examination, tissue biopsy, and others. The immunodiagnosis is
classified into enzyme-linked immune sorbent assay (ELISA), and
immunodiffusion, and others.
On the basis of the treatment, the global chromoblastomycosis
treatment market is segmented into surgery, antifungal drugs, amphotericin B
therapy, thermotherapy, laser therapy, photodynamic therapy, adjuvant therapy,
and others. The surgery is classified into cryosurgery, curettage,
electrodesiccation, surgical excisions, and others. Furthermore, the antifungal
drugs are categorized into oral itraconazole, oral terbinafine, posaconazole,
isavuconazole, and others.
On the basis of the end-user, the market is segmented into
hospitals & clinics, medical institutes, research organization, and others.
Regional
Analysis
The global chromoblastomycosis treatment market consists of
countries namely the Americas, Europe, Asia Pacific, and the Middle East &
Africa.
The Americas dominate the global chromoblastomycosis
treatment market owing to a huge patient population for chromoblastomycosis and
well-developed healthcare sector. This disease commonly affects the
agricultural workers in rural regions of South America, Central America, and
North America.
The European region is the second largest market for the
global chromoblastomycosis treatment owing to the rising occurrence of fungal
infections among the patients, and advancements in the surgeries procedure and
the use of surgical devices. It was estimated that about 20% of these cases were
found in countries such as the Czech Republic, Romania, and Finland.
Asia Pacific is the fastest growing region for
chromoblastomycosis treatment market due to increasing prevalence of fungal
infections, and regional expansion for the development of this market. Japan is
considered to exhibit the highest prevalence rate for chromoblastomycosis in
the Asia Pacific region.
Key Players:
Some of key the players in the global chromoblastomycosis
treatment market are Astellas Pharma (Japan), Biocon Limited (India),
Abbott Laboratories (U.S.), Merck Sharp and Dohme (U.S.), Gilead Sciences
(U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.), Bayer AG
(Germany), Lonza Group (Switzerland), Sanofi (France), F. Hoffman La Roche
(Switerzland), Cadila Pharmaceuticals Limited (India), Johnson &
Johnson (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switerzland), and others
Get Your Customized Report @ https://www.marketresearchfuture.com/reports/chromoblastomycosis-treatment-market-5685
Table Of
Content
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
TOC
Continued…!
Get
Discount @
About
US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone:
+1
646 845 9312
Comments
Post a Comment